deltatrials
Completed PHASE3 NCT00196859

Study in Elderly Patients With Early Breast Cancer (ICE)

Ibandronate With or Without Capecitabine in Elderly Patients With Early Breast Cancer

Sponsor: AstraZeneca

Conditions Breast Cancer
Interventions Ibandronate Ibandronate, Capecitabine
Updated 6 times since 2017 Last updated: Jul 16, 2014 Started: Jun 30, 2004 Primary completion: Jan 31, 2014 Completion: Jan 31, 2014

Listed as NCT00196859, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by AstraZeneca, it has been updated 6 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Apr 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • GBG Forschungs GmbH
  • Hoffmann-La Roche
Data source: GBG Forschungs GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Mönchengladbach, Germany